Biomarkers for hepatitis from immunotherapy
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study looks for certain markers in the blood that can help diagnose liver inflammation caused by immunotherapy. It aims to better understand this side effect and how to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are being treated with immune checkpoint inhibitors (a type of immunotherapy) for cancer, and have developed liver inflammation (hepatitis) as a side effect.
- Your liver inflammation is severe (grade 3 or 4, meaning your liver enzymes are at least 5 times the normal level).
- You have not yet started treatment for this liver inflammation, or you started it less than 30 days ago.
- A liver biopsy is possible for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
This study follows people who develop liver inflammation (hepatitis) after starting immunotherapy for cancer. It helps doctors understand how often this happens and how to manage it.
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
Hear when a new Immune-Mediated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.